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ABSTRACT
Purpose To determine if solid lipid nanoparticles represent a
viable strategy for local delivery of poorly water soluble and
unstable chemopreventive compounds to human oral tissues.
Methods Nanoparticle uptake and compound retention
evaluations employed monolayer-cultured human oral squa-
mous cell carcinoma (OSCC) cell lines and normal human oral
mucosal explants. Feasibility of nanoparticle delivery was also
evaluated with respect to the presence of phase-III efflux
transporters in normal oral mucosal tissue and OSCC tissues.
Results Functional uptake assays confirmed significantly greater
internalization of nanoparticle-delivered fluorescent probe
relative to free-fluorescent probe delivery, while concurrently
demonstrating nanoparticle uptake rate differences among the
OSCC cell lines and the phagocytic control human monocyte
cell line. Mucosal explants exhibited nanoparticle penetration
and internalization in the spinous and basal epithelial layers
(7/10 specimens), and also exhibited the presence of the
phase-III efflux transporters multidrug resistance-associated
protein 1 (MRP1) and breast cancer resistance protein (BCRP).
Conclusions These data confirm nanoparticle internalization
by OSCC cells and support the premise that nanoparticle-
based delivery provides higher final intracellular levels relative
to bolus administration. Furthermore, the penetration and
subsequent internalization of nanoparticles within the prolifer-
ating basal layer cells demonstrates the feasibility of nanoparticle
formulations for local delivery and stabilization of oral chemo-
preventive compounds.
KEY WORDS effluxtransporter.localdelivery.mucosal
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ABBREVIATIONS
μg microgram
μl microliter
μM micromolar
BCRP breast cancer resistance protein
BODIPY-NPs BODIPY FL C12-nanoparticles
COX-2 cyclooxygenase 2
FBR freeze-dried black raspberry
FluoSpheres biotin-coated yellow-green 200 nm
FluoSpheres®
free-IDA free idarubicin
gm gram
IDA-NPs idarubicin nanoparticles
mg milligram
ml milliliter
MRP1 multidrug resistance-associated protein 1
nm nanometer
nM nanomolar
OSCC oral squamous cell carcinoma
P-gp P-glycoprotein
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INTRODUCTION
Due to their visibly accessible location and characterized
progression from oral dysplastic lesions to oral squamous
cell carcinoma, premalignant oral epithelial lesions present
an ideal opportunity for chemoprevention. Despite these
obvious clinical advantages, results from previously con-
ducted oral cancer chemoprevention trials have generally
been disappointing (1–8). The majority of these previous
clinical trials relied on systemic agent administration and
did not determine whether or not therapeutically relevant
chemopreventive compound levels were achieved at the
treatment site (1–5). It is therefore impossible to distinguish
whether these negative data reflect the use of ineffective
chemopreventive compounds or lack of compound bio-
availability at the target tissue (9). In contrast to systemic
administration, local delivery of therapeutic compounds
introduces the potential to maximize local effects while
negating systemic consequences.
Our laboratories recently completed a Phase I/II clinical
trial to evaluate the effects of a topically applied 10%
freeze-dried black raspberry (FBR) aqueous gel on prema-
lignant oral lesions (10,11). Topical FBR gel application
(2 gm daily, applied as 0.5 gm q.i.d. for 6 weeks) effectively
delivered therapeutically relevant levels of chemopreventive
compounds, i.e., anthocyanins, to the oral target tissues
(12). Treatment resulted in histopathologic regression,
significant reduction in loss of heterozygosity indices at
tumor-suppressor-gene-associated loci, decrease in lesional-
associated angiogenesis, and significant reduction of cyclo-
oxygenase 2 (COX-2) protein in treated dysplastic oral
epithelium (10,11). Not all trial participants, however,
derived comparable chemopreventive benefits (10,11).
Consequently, we are currently investigating the prospect
of combining additional compounds with FBR treatment,
e.g., fenretinide, to enhance overall clinical responsiveness.
Notably, levels of beta-carotene, a vitamin A precursor, are
negligible within the FBR formulations (13).
By virtue of its proapoptotic and differentiation-inducing
effects, the synthetic vitamin A analog, N-(4-hydroxyphenyl)
retinamide (fenretinide), is a promising chemopreventive
compound for premalignant epithelial lesions (14,15). While
fenretinide provides the antineoplastic effects of vitamin A,
it also demonstrates a decreased resistance-induction and
toxicity profile (14). Furthermore, while a high fenretinide
concentration (10 μM) induced apoptosis through a
receptor-independent pathway, a low fenretinide concentra-
tion (1 μM) promoted epithelial differentiation through a
receptor-dependent mechanism (15). Fenretinide’s receptor-
independent induction of apoptosis presents the potential for
long-term efficacy due to the lack of acquired receptor-
resistance. This prospect is particularly appealing provided
that oral cavity chemoprevention will likely entail sustained-
duration treatment. A recent clinical trial, however, admin-
istered systemic high-dose fenretinide, which resulted in
minor toxicities and minimal histopathological improvement
within the enrolled patients (5). This fenretinide study did
not determine fenretinide levels in the target tissues (5).
While the oral cavity is richly vascularized, the surface
epithelium itself is avascular. Consequently, topical delivery
of chemopreventive compounds will likely provide therapeu-
tically relevant concentrations in the target tissue, i.e.,
epithelial layers, without relying on perfusion from the
underlying vasculature and minimizing the toxicities associ-
ated with systemic exposure.
Based on their complementary mechanisms of action
(i.e., FBR compounds exhibit strong antioxidant and anti-
inflammatory properties, and fenretinide induces apoptosis
and differentiation), there is the prospect for inter-agent
additive or synergistic chemopreventive effects with con-
current or sequential administration of FBR and fenreti-
nide. Fenretinide, however, is poorly water soluble and
prone to hydrolysis. Thus, it may be an ideal candidate for
the entrapment in nanoparticles which serve both to
enhance the apparent solubility and protect the drug from
an aqueous environment (16).
Prior to formulation development and evaluation of solid
lipidnanoparticlescontainingfenretinide,itwasfirstnecessary
to establish the feasibility of using nanoparticles for local drug
deliverytotheoralmucosa.Intheseproof-of-principlestudies,
two types of nanoparticles were studied: solid lipid nano-
particles (SLN) incorporating either idarubicin or BODIPY®
FL C12 as model fluorescent probes and polystyrene nano-
particles (FluoSpheres®). Although human oral mucosa
contains cells with established phagocytic abilities, e.g.,
Langerhans cells and endothelial cells, questions remain
regarding the capacity for oral epithelial cell nanoparticle
internalization, particularly with regard to the intact strati-
fied squamous oral epithelium. Our data, which show that
monolayer human oral squamous cell carcinoma (OSCC)
cells internalize nanoparticles and confirm that nanoparticles
penetrate to the basal and superficial underlying connective
tissue layers of intact normal oral epithelium, establish the
prospect for nanoparticle formulation use in a local oral
cancer chemoprevention strategy.
MATERIALS AND METHODS
Materials
Cell culture medium: Dulbecco’s modified Eagle’s medium
and Hams F12 medium (DMEM/F12), RPMI 1640, fetal
Local Nanoparticle Delivery to Oral Mucosa 1225bovine serum (FBS), and gentamicin were purchased from
GIBCO® (Grand Island, NY, USA). Eagle’s Minimum
Essential Medium (EMEM) was purchased from American
TypeCellCulture(ATCC,Manassas,VA,USA).BODIPY®
FL C12 and 4′,6-diamidino-2-phenylindole (DAPI) were
supplied by Invitrogen (Carlsbad, CA, USA). Biotin-coated
yellow-green 200 nm FluoSpheres® and insulin from bovine
pancreas were purchased from Sigma-Aldrich (Saint Louis,
MO, USA). Vectashield mounting medium, Vectastain ABC
reagent, DAB substrate, and biotinylated horse anti-mouse
secondary antibody were obtained from Vector Laboratories
(Burlingame, CA, USA). E-cadherin monoclonal antibody,
Breast Cancer Resistance Protein (BCRP) monoclonal
antibody [BXP-21], P-glycoprotein (P-gp) monoclonal anti-
body [C219 and JSB-1], and Texas Red anti-mouse
secondary polyclonal antibody were purchased from
Abcam (Cambridge, MA, USA). Multidrug resistance-
associated protein 1 (MRP1) monoclonal antibody
[QCRL-1], β-actin monoclonal antibody, goat anti-mouse
IgG-HRP, donkey anti-goat IgG-HRP, rat liver extract,
and Blotto non-fat dry milk were obtained from Santa
Cruz Biotechnology® (Santa Cruz, CA, USA). Mammalian
protein extraction reagent (M-PER) was obtained from
Pierce Protein Research Products (Thermo Fisher Scientific,
Rockford, IL, USA). ECL plus Western blotting detection
system was obtained from Amersham GE Healthcare Life
Sciences (Buckinghamshire, UK). CL-Xposure films were
obtained from Kodak (Rochester, NY, USA). Immun-Blot
Polyvinylidene Fluoride (PVDF) Membranes were obtained
from Bio-Rad Life Science Research (Hercules, CA, USA).
FIBRACOL-Plus sponges were obtained from Johnson and
Johnson (Somerville, NJ, USA).
Cell Culture
Four human cell lines derived from squamous cell carcino-
mas of the tongue (SCC4 [CRL-1624], SCC9 [CRL-1629],
SCC15 [CRL-1623], and SCC25 [CRL-1628]), MCF7
human breast adenocarincoma cells [HTB-22], HCT-15
human colorectal adenocarcinoma cells [CCL-225], and
U-937 human monocytes [CRL-1593.2] were obtained
from American Type Cell Culture. Previous studies in our
laboratory have confirmed that the four human oral
squamous cell carcinoma cell lines retain features of intact
oral mucosa inclusive of functional Phase I and II carcinogen
metabolizing enzymes, inducible nitric oxide synthase and
cyclooxygenase-2 (COX-2) enzymes, and a responsive thiol-
redox status (17–19). Oral squamous cell carcinoma (OSCC)
cells were cultured in DMEM/F12 medium supplemented
with10%heat-inactivatedFBSat37°C,5%CO2.M C F 7c e l l s
were cultured in EMEM supplemented with 0.01 mg/ml
bovine insulin and 10% heat-inactivated FBS at 37°C, 5%
CO2. HCT-15 cells and U-937 monocytes were cultured in
RPMI-1640 medium supplemented with 10% heat-
inactivated FBS at 37°C, 5% CO2.
Human Oral Tissue Collection
Twenty-five normal human oral mucosal tissues were
obtained from patients undergoing elective oral surgical
procedures. Ten specimens were used for evaluation of
nanoparticle penetration, and 15 specimens were used for
Western blot and immunohistochemistry analysis of phase-
III efflux transporter expression. Furthermore, five human
OSCC specimens, which were obtained from the Ohio
State University Comprehensive Cancer Center Tissue
Procurement Service, were used for immunohistochemistry
analysis of phase-III efflux enzyme expression. Human
subject participation was in accordance with the Ohio State
University Institutional Review Board approval and followed
the tenets of the Declaration of Helsinki 1964.
Formulation of Idarubicin and BODIPY FL C12 Solid
Lipid Nanoparticles
The idarubicin nanoparticles (IDA-NPs) were formulated
as previously described by Ma et al. (20), and BODIPY
FL C12-NPs were formulated by identical methods. IDA-
NPs were composed of idarubicin hydrochloride (0.2 mg
idarubicin/ml), sodium tetradecyl sulfate (0.159 mg/ml),
emulsifying wax (2 mg/ml), Polyoxyl 20-stearyl ether
[Brij 78] (2.3 mg/ml), and D-alpha-tocopheryl polyethylene
glycol 1,000 succinate [vitamin-E TPGS] (3 mg/ml).
Idarubicin nanoparticles had an average size of 95 nm±
0.2, polydispersity index of 0.157 and zeta potential of
−13.7 mV±2.1, and were stable over at least seven days at
4°C. Idarubicin was chosen as a model probe for these
studies since the formulation had already been developed
and idarubicin is highly fluorescent.
The BODIPY nanoparticles (BODIPY-NPs) were com-
posed of BODIPY FL C12 (50 μg/ml), emulsifying wax
(2mg/ml), and Polyoxyl20-stearyl ether[Brij 78](4.0 mg/ml).
BODIPY-NPs had an average size of 86 nm, polydispersity
index of 0.043, zeta potential of −13.8 mV±0.16, and were
stableoveratleastsevendaysat4°C.PleaserefertoTableI for
a complete description of nanoparticle characteristics and
experimental applications.
Qualitative Assessment of Solid Lipid Nanoparticle
and FluoSphere Internalization in OSCC Cell
Monolayer
OSCC cells were seeded in 8-well LabTek chamber slides
at 1×10
5 cells/well. The cells were incubated with nano-
particles at varying concentrations and time points, as
shown in Table I, at 37°C, 5% CO2 in DMEM/F12
1226 Holpuch et al.medium supplemented with 10% heat-inactivated fetal
bovine serum. Following incubation and nuclear staining,
cell samples were mounted in Vectashield mounting medium
and visualized using wide-field fluorescence microscopy
(Olympus BX51); images were captured with a Nikon DS-
Fi1 high-resolution digital camera.
Quantitative Assessment of Solid Lipid Nanoparticle
and FluoSphere Internalization in OSCC Cell
Monolayer
OSCC cells were seeded in 96-well plates at 1×10
5 cells/well,
and treated in triplicate with nanoparticles at varying concen-
trations and time points (Table I). Cells were washed with
phosphate-buffered saline, extracellular fluorescence quenched
with a 0.08% Trypan blue solution, and internal fluorescence
was quantified using an LS50B luminescence spectrometer
(Perkin Elmer; Waltham, MA, USA), and more recent
quantitative studies (FluoSpheres) with a FLUOstar Omega
microplate reader (BMG Labtech, Durham, NC).
Evaluation of FluoSphere Nanoparticle Penetration
and Uptake in Oral Mucosal Tissue Explants
To determine whether or not topically applied nano-
particles could penetrate the outer epithelial layers and
reach the chemopreventive targets, i.e., proliferating basal
and peribasilar epithelial cells, oral mucosal tissues were
obtained from ten persons undergoing elective oral surgical
procedures. Mucoadhesive bi-layer thin-film composites
(TFC) were formulated as described in our previous reports
(21,22). The TFCs were cut with a circular arch punch to a
diameter of 7 cm and subsequently trimmed with a scalpel
to the corresponding oral explant size. Tissue explant
Table I Nanoparticle Characteristics and Experimental Application
Nanoparticle Size (ζ-potential) Fluorescence (ex/em) Nanoparticle composition Experimental application
Solid lipid NPs
Idarubicin-NP
(IDA-NPs)
95 nm (−13.7 mV±2.1) 485 nm/542 nm Idarubicin HCl, Sodium Tetradecyl
Sulfate (STS), emulsifying wax,
Brij® 78, D-alpha-tocopheryl
polyethylene glycol 1,000 succinate
(Vitamin E TPGS)
Initial qualitative (Fig. 3A and B) and
quantitative (nanoparticle versus bolus
delivery) (Fig. 4) studies in SCC4,
SCC9, and SCC15 cell lines. Following
30 min, 2,500 nM IDA-NP incubation
for qualitative analysis, nuclei were
stained with 300 nM DAPI.
Solid lipid NPs
BODIPY® FL C12
NP (BODIPY-NPs)
86 nm (−13.8 mV±0.16) 500 nm/510 nm BODIPY® FL C12, Sodium
Tetradecyl Sulfate (STS),
Emulsifying wax, Brij® 78
Qualitative internalization study in
SCC4 and SCC15 cell lines. Following
6h ,1μg BODIPY-NP incubation,
exogenous fluorescence was
quenched with 0.08% Trypan blue
(49) and nuclei stained with 300 nM
DAPI (Fig. 3C and D).
FluoSphere® NPs
yellow-green
210 nm (−9.9 mV±
1.65) (33)
505 nm/515 nm Biotin-labeled, fluorescein-loaded,
polystyrene nanoparticles
Qualitative internalization study in
SCC4 cell line and intact human oral
mucosal epithelium. In monolayer
studies, following 2 h incubation with
1.0×10
7 FluoSpheres, cells were
incubated overnight at 4°C with 1:50
dilution of E-cadherin monoclonal
antibody, and subsequently stained for
1 h at room temperature with 1:500
dilution of Texas Red anti-mouse
secondary antibody (Fig. 3E and F).
Immunocytochemistry (Fig. 3G and H)
in SCC4 cell line and immunohisto-
chemistry (Fig. 8) in human oral
mucosal explants were conducted to
exhibit consistency in FluoSphere size
and penetration in intact mucosal
epithelium. Quantitative analysis of
FluoSphere uptake in SCC4 (n=10),
SCC9 (n=10), SCC15 (n=10), and
U-937 monocytes (n=10) utilized a
previously identified concentration of
2.0×10
7 FluoSpheres/1.0×10
5 cells
for 1, 6, and 24 h (Fig. 7).
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orientation and TFC placement. Explants were then placed
on a FIBRACOL-Plus sponge in DMEM/F12 supple-
mented with 10% heat-inactivated FBS and 40 μg/ml
gentamicin. Fifty-million tissue-fixation-stable FluoSpheres
were post-loaded onto the TFC by aliquoting 15 μlo f
suspension onto the mucoadhesive layer of the TFCs and
air-dried at room temperature for 45 min. The FluoSphere
p o s t - l o a d e dT F C sw e r et h e np l a c e dd i r e c t l yo nt h e
epithelial surface of the oral explant, as shown in Fig. 1.
The explants were incubated with the post-loaded TFCs at
37°C, 5% CO2 for 3 h. Following incubation, the TFCs
were removed, and the explants were washed five times in
1×PBS, subsequently fixed with 10% formalin, followed by
standard tissue processing. Control tissues received identical
TFC treatment with the exception of FluoSphere addition.
The potential for artifact-induced FluoSphere cross-
contamination was alleviated by initially sectioning the
nanoparticle-free control tissues and thoroughly cleaning
the microtome blade after sectioning each successive Fluo-
sphere tissue explant specimen. To avoid the prospect for
FluoSphere incorporation from the sides of the explant,
histologic sections were obtained from the deeper portions
of the specimens. Tissue sections were then deparaffinized,
rehydrated, and counterstained with hematoxylin and
eosin. For each sample, nanoparticle penetration into the
respective epithelial compartments (i.e., surface third,
middle third, basal third) and underlying connective tissue
was determined, as shown in Fig. 2.
Determination of Phase-III Efflux Transporter
Expression in Normal Human Oral Mucosal Tissue
and Cultured Human OSCC Cells by Western
Blot Analysis
OSCC cells (SCC4, SCC9, SCC15, SCC25), 15 normal
human oral mucosal samples, MCF-7 cells (BCRP/MRP1
positive control), HCT-15 cells (P-gp positive control), or
rat liver extract (MRP1 positive control) were cultured/
collected as described and protein extracted with M-PER®.
Protein samples were quantified using the Bradford protein
assay (23)a n d3 0μg loaded onto a 10% SDS-polyacrylamide
gel and subjected to electrophoresis. Following electrotransfer
onto PVDF membranes, the blots were blocked for 1 h at
room temperature with 1× Tris-buffered saline containing
0.2% Tween-20 and 5% non-fat dry milk, and subsequently
incubated overnight with the respective primary antibody
dilution (BCRP 1:250, MRP1 1:200, P-gp 1:100, β-actin
1:20,000). Immune complexes were detected by incubation
for 1 h at room temperature with horseradish peroxidase-
linked secondary antibody (goat anti-mouse IgG-HRP
1:1,000, donkey anti-goat IgG-HRP 1:2,000). Immuno-
reactive bands were detected by 5 min incubation with
ECL-plus detection system and subsequent exposure on
CL-Xposure films.
Confirmation of MRP1 and BCRP Expression
in Normal Human Oral Mucosa and OSCC Specimens
via Immunohistochemistry
Paraffin-imbedded tissues were deparaffinized and rehy-
drated, and endogenous peroxidase activity was blocked by
pretreatmentwith3%H2O2, followed by microwave processing
to facilitate antigen retrieval. Sections were subsequently treated
with 5% normal serum, 1% bovine serum albumin, and 0.05%
Tween-20 for 1 h, and then incubated with either the primary
antibody (MRP1: 1:50, BCRP 1:20, Pgp: 1:100) or PBS
(negative control) at 4°C overnight. Next, samples were
incubated with the respective biotinylated secondary
antibody for 1 h at room temperature. Vectastain ABC reagent
Fig. 1 Orientation of normal human oral mucosal tissue explants and
FluoSphere incubation setup. A Mucosal explant surface epithelium was
initially identified prior to incubation setup. Explants measured, on average,
5 mm in diameter. B Mucosal explants were oriented epithelial side up in
a fibrocollagen sponge partially immersed in culture medium. FluoSphere
(5.0×10
7) post-loaded mucoadhesive thin-film composites were then
placed directly on the epithelial surface and incubated at 37°C for 3 h.
Fig. 2 The quantification scheme used to assess FluoSphere penetration
divided the oral stratified squamous epithelium of mucosal explants into a
surface third, middle third, and basal third. Nanoparticle penetration through
the basement membrane was recorded in the connective tissue category.
1228 Holpuch et al.was then applied and sections incubated for 30 min. Immuno-
reactions were visualized using the DAB substrate, followed by
hematoxylin counterstaining. Images were captured using a
Nikon DS-Fi1 high-resolution digital camera and analyzed
using Image-Pro Plus 6.2 software (Media Cybernetics,
Bethesda, MD, USA).
Statistical Analysis
IDA-NP versus free-IDA internalization was compared using
the Mann Whitney U two-tailed test. Individual cell line
FluoSphere internalization was analyzed using the Wilcoxon
one-tailed signed rank test. Comparison of inter-cell line
FluoSphere uptake was compared using the Kruskal-Wallis
Nonparametric Analysis of Variance, followed by a Dunn’s
Multiple Comparisons post-test.
RESULTS
IDA-Nanoparticles Internalized and Retained
at High Levels in Cultured OSCC Cells
The initial treatment of OSCC cells with IDA-NPs in
LabTek chamber slides suggested that the SLNs were
internalized by the cells in monolayer (Fig. 3A and B).
Furthermore, the quantitative comparison of IDA-NP versus
free-IDA internalization exhibited an accelerated uptake of
free-IDA compared to IDA-NP at 1 h [1,000 nM: average
free-IDA internalization (21.08±5.33); IDA-NP internali-
zation (12.87±4.32) p<0.002, n=18], but the overall
maximum retention was obtained with nanoparticle deliv-
ery at 6 h [IDA-NP internalization: 2,500 nM: 43.53±8.42,
5,000 nM: 64.44±12.71; Free-IDA internalization:
2,500 nM: 27.61±5.66, p<0.01, n=18; 5,000 nM: 31.06±
7.24, p<0.001, n=18]. Interestingly, free-IDA internaliza-
tion exhibited a plateau effect after 6 h, while the IDA-NP
portrayed a dose- and time-dependent uptake with maximal
levels obtained at the highest dose and longest incubation
time (Fig. 4). These data, which showed higher final
intracellular levels with SLN delivery, suggested the potential
for SLNs to overcome phase-III transporter-mediated efflux
(P-gp, BCRP, and/or MRP1), while free-IDA appeared
susceptible to the efflux mechanism.
Expression of Phase-III Transporters (MRP1
and BCRP) in Normal Oral Mucosal Tissue, OSCC
Tissue, and Cultured OSCC Cells (MRP1)
Subsequent Western blot and immunohistochemistry anal-
yses to evaluate for the presence of phase-III transporters
showed a cell- and tissue-dependent specificity. Western
blot analysis confirmed the presence of BCRP in all (15/15)
normal human oral mucosal tissues (Fig. 5A), which also
exhibited higher levels relative to the unchallenged MCF-7
positive control. In contrast, the OSCC cells did not show a
BCRP-corresponding band (data not shown). Furthermore,
BCRP immunohistochemistry exhibited strong staining in
Fig. 3 Representative photomicrographs of SLN and FluoSphere internalization studies in monolayer-cultured human OSCC cells. A IDA-NP
internalization negative control, cells were not treated with SLNs. Nuclei (blue) were stained with 300 nM DAPI. B SCC4, SCC9, and SCC15 cells
internalized IDA-NPs (green) following 30 min incubation with 2500 nM IDA-NPs (only SCC9 shown). C BODIPY-NP internalization negative control. D
SCC 4 and SCC15 cells internalized BODIPY-NPs (green) following 6 h incubation with 1μg BODIPY-NPs and subsequent quenching of extracellular
fluorescence with 0.08% Trypan blue (only SCC15 shown). E FluoSphere internalization negative control with E-cadherin (to delineate cell boundaries)
immunofluorescent staining. F SCC4 cells internalized FluoSpheres (green) following 2 h incubation with 1.0×10
7 FluoSpheres. G FluoSphere
immunocytochemistry negative control. H Immunocytochemistry evaluation of SCC4 cell internalization of FluoSpheres (arrows) to confirm size
consistency utilizing both fluorescence and immunocytochemical analyses.
Local Nanoparticle Delivery to Oral Mucosa 1229the basal and spinous layers of the normal oral epithelium
in 9/10 specimens (Fig. 6A) and showed selective staining at
the periphery of the tumor nests in 5/5 OSCC specimens
(Fig. 6B).
The MRP1 Western blot analysis, on the other hand,
exhibited expression in all (15/15) normal oral mucosal
tissues (Fig. 5B) and to varied intensities in 4/4 OSCC cell
lines (Fig. 5C). While the intact molecular weight of MRP1
is 190 kDa, our findings were consistent with the literature
which reports that MRP1 is sensitive to cleavage into two
fragments of approximately ∼75 kDa and ∼120 kDa (24).
Furthermore, MRP1 immunohistochemistry also revealed
positive staining in the basal and spinous layers of epithelium
in 8/8 normal oral mucosal tissues (Fig. 6C) and staining
throughout the tumor nests in 3/5 OSCC specimens
(Fig. 6D). Additional Western blot and immunohistochem-
ical analyses confirmed the absence of P-glycoprotein in 7/7
normal human oral mucosal tissues (Fig. 6E), 3/3 OSCC
tissues (Fig. 6F), and 4/4 OSCC cells (Western blot not
shown) relative to the positive control HCT-15 cell line and
human minor salivary gland tissue.
Qualitative Confirmation of Solid Lipid Nanoparticle
Internalization by Monolayer OSCC Cells
The capacity for OSCC cells in monolayer culture to
internalize model SLNs was analyzed using wide-field
fluorescent microscopy. Our data, which demonstrated
the presence of intracellular fluorescent nanoparticles
following quenching of non-internalized, extracellular par-
ticles with Trypan blue, confirmed the definitive internal-
ization of the BODIPY-NPs in both of the OSCC cell lines
evaluated (Fig. 3C and D).
Fixation-Stable FluoSpheres Readily Internalized
by Monolayer Oral SCC Cells
FluoSphere uptake in monolayer OSCC cells was qualita-
tively assessed by both fluorescence microscopy (Fig. 3E
and F) and immunocytochemistry (Fig. 3G and H). Similar
to the smaller diameter SLN studies, i.e., 95 nm IDA-NP
Fig. 4 Idarubicin-nanoparticle delivery provided higher, sustained levels of
intracellular idarubicin relative to free-idarubicin delivery in human OSCC
cells. The internalization of free-IDA was more rapid than IDA-NP after
1 h at 1000 nM (free-IDA: 21.08±5.33 vs. IDA-NP: 12.87±4.32).
However, the maximum uptake of IDA-NP was greater than free-IDA
after 6 h at 2500 nM (IDA-NP: 43.53±8.42 vs. free-IDA: 27.61±5.66)
and 5000 nM (IDA-NP: 64.44±12.71 vs. free-IDA: 31.06±7.24). [Data
collected from three oral SCC cell lines, mean ± SD, n=18, *P≤0.01
†P≤0.002,
‡P≤0.001; IDA-NP samples compared to free-IDA samples;
Mann-Whitney U two-tailed Test].
Fig. 5 Evaluation of phase-III efflux transporter expression in normal
human oral mucosa and human OSCC cells via Western blot analysis. A
The presence of BCRP in 15 normal oral mucosal samples (DB016-
DB020 are five representative samples) was confirmed relative to MCF-7
positive control. B MRP1 expression was confirmed in 15 normal oral
mucosal samples (DB016-DB020 are five representative samples) relative
to rat liver extract and MCF-7 positive controls. C MRP1 expression was
also confirmed in SCC4 and SCC9 cells, and to a lesser extent in SCC15
and SCC25 cells. While the expected MRP1 molecular weight is 190 kDa,
these data are consistent with the literature describing cleavage fragments
of ∼75 kDa and ∼120 kDa (24).
1230 Holpuch et al.and 86 nm BODIPY-NP, the larger diameter FluoSpheres,
200 nm, were also internalized by OSCC cells in monolayer
(3/3 cell lines).
Corresponding quantitative analyses of FluoSphere
uptake were both cell-origin- and cell-line-dependent. As
would be anticipated based on their phagocytic origin,
U-937 cells exhibited the highest FluoSphere internaliza-
tion at all time points, and all OSCC cell lines internalized
FluoSpheres, albeit to a lesser extent. While all OSCC cell
lines demonstrated quantifiable nanoparticle uptake at 6
and 24 h (Fig. 7A and C), the greatest internalization was
apparent in the SCC4 cell line (6 h: 9.84%, 24 h: 18.38%
relative to the uptake of U-937 monocytes, Fig. 7B and D).
Not unexpectedly, at the 6 h time point, monocytes had
internalized the largest amount of FluoSpheres, resulting
in significantly greater internalization relative to SCC4
(p<0.05), SCC9 (p<0.001), and SCC15 cells (p<0.001).
Although monocyte intracellular levels of FluoSpheres
decreased from the 6 to 24 h time points, monocyte levels
were still significantly higher at 24 h relative to all oral SCC
cells (SCC4: p<0.01, SCC9: p<0.001, SCC15: p<0.001).
Appreciable cell-line-dependent heterogeneity was ob-
served among the OSCC cell lines. Although the 1 h time
point did not provide ample time for internalization in the
SCC9 and SCC15 cell lines, the SCC4 cells exhibited
considerable uptake (data not shown). This trend also
translated to a significantly higher rate of FluoSphere
internalization in SCC4 cells relative to SCC9 and SCC15
cells at the 6 h time point (p<0.01). At the 24 h time point,
however, total intracellular levels of FluoSpheres in SCC4
cells were reduced relative to their 6 h time point. In
contrast, comparison of the 6 h relative to 24 h time points
in SCC9 and SCC15, cells showed increased intracellular
FluoSphere levels. Furthermore, all 6 and 24 h samples
individually demonstrated significant uptake, as shown in
Fig. 7A and C (6 h: SCC4: p<0.001, SCC9: p<0.025,
Fig. 6 Evaluation of phase-III
efflux transporter expression in
normal human oral mucosa
and human OSCC tissue via
immunohistochemistry. The pres-
ence of BCRP (A) and MRP1 (C)
is evident in the basal and spinous
layers of the normal oral
epithelium, which are key sites for
the protection of cells actively
replicating DNA. Note, this tissue
is from the same specimen, i.e.,
DB020, used in the Western
blots, indicating the focused
expression of these efflux pumps
in the epithelium rather than
connective tissue. The OSCC
tissue samples also express BCRP
(B) and MRP1 (D), which are
both focused in the malignant
epithelial cell tumor nests.
Notably, P-gp expression is absent
in normal oral mucosal tissue (E)
and OSCC tissue (F), which was
also confirmed by Western blot
analyses (data not shown).
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SCC9: p<0.001, SCC15: p<0.001, U-937: p<0.001).
FluoSphere Nanoparticles Penetrate Intact
Human Oral Stratified Squamous Epithelium
and are Retained in Basal Cells and Underlying
Connective Tissue
Application of fixation-stable FluoSpheres to mucosal
explants (n=10) demonstrated the capacity for nanoparticle
penetration and subsequent internalization by intact human
oral epithelium. In addition, nanoparticle retention was not
restricted to the superficial layer of the surface epithelium.
Intact nanoparticles were visualized in the superficial third
of the epithelium in 10/10 explants, the middle epithelial
third in 7/10 explants, and the basilar third in 7/10
explants. Notably, intact nanoparticles were also observed
in the superficial underlying connective tissue in 7/10
explants (Fig. 8 and Table II), implying penetration of
intact basement membranes. Due to the need for surgery at
multiple sites, one tissue donor (patient 5) donated speci-
mens from multiple tissue sites, of which all four
demonstrated full-thickness penetration of the entire epi-
thelium by FluoSpheres.
DISCUSSION
Most oral topical agents rely on aqueous-based gels as delivery
vehicles, e.g., Lidex®, Temovate®, and the FBR gel used in our
phase I/II clinical trials (10,11,25). While gels represent the
most common oral delivery strategy, oral rinses (6), local
injections (26), and mucoadhesive patches (21,22)a r ea l s o
frequently used. Due to the lack of compatibility, it is
challenging to formulate poorly water soluble and/or unstable
compounds, such as fenretinide, in topical aqueous-based
delivery vehicles (27). This shortcoming in topical oral drug
delivery was the basis for these current studies, which assessed
the feasibility of nanoparticle-based formulations for local
delivery of such drugs to the oral mucosa.
Fig. 7 Comparison of FluoSphere internalization by human OSCC cells and human monocytes. FluoSphere internalization was cell-line-dependent, with
SCC4 cells exhibiting significantly greater internalization after 1 h (data not shown) and 6 h (A) incubations compared to SCC9 and SCC15 cells. As
expected, human monocytes’ FluoSphere uptake was significantly greater than all OSCC cell lines at 6 h (B). After 24 h of FluoSphere incubation,
however, SCC4 cells exhibit a decrease of intracellular FluoSphere amount (possibly due to MRP1-mediated efflux), while the SCC9 and SCC15 cells
exhibit steady internalization over the full 24 h time course (C). Furthermore, at 24 h, OSCC cells demonstrate increased internalization relative to human
monocytes, but the overall decrease in monocyte internalization at 24 h is possibly attributed to decreased cell viability. [mean ± SEM, n=10,
†P≤0.025,
‡P≤0.001; Wilcoxon Signed Rank, one-tailed test, H0: μ=0].
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ably to previous studies, which demonstrated that cultured
human oral epithelial cells and dissociated oral and
esophageal epithelial cells internalized variably sized
(10 nm–100 nm) fluorescently labeled polystyrene nano-
particles in a dose-dependent fashion (28–31). Based on
their lack of biodegradability and the covalent linkage of
fluorescein to polystyrene, FluoSpheres (i.e., polystyrene
nanoparticles) represent a convenient tool to evaluate in vitro
and ex vivo endocytosis (32). The inability, however, to
metabolize polystyrene and the potential for polystyrene
nanoparticle interference with cell metabolism, e.g., inhibi-
tion of cytochrome P450 complexes, precludes the use of
such nanoparticle formulations for local oral delivery
(33). It is therefore necessary to identify a nanoparticle
delivery system that has appropriate biocompatibility. The
model SLNs formulated by our labs (i.e., IDA-NPs and
BODIPY-NPs) have been shown to have excellent hemo-
Fig. 8 FluoSphere penetration in
representative samples of intact
normal oral stratified squamous
epithelium. Following an elective
oral surgical procedure, normal
oral mucosa was collected and
bisected (n=10 samples). One
half of the full-thickness mucosal
tissue was used as an explant-
matched negative control (A),
which was incubated in the
absence of FluoSpheres. The
other half of the matched mucosal
tissue was used for the analysis of
FluoSphere penetration and inter-
nalization (B), as described in
Fig. 2 and presented in Table II.A s
demonstrated by the arrows (B),
the nanoparticles penetrate the full
thickness of oral epithelial layers
and basement membrane.
Furthermore, immunohistochem-
istry analysis of FluoSphere-treated
explants show full epithelial pene-
tration and intracellular retention
of nanoparticles in MRP1 (C) and
BCRP (D) expressing tissue.
Table II FluoSphere® Penetration in Normal Human Oral Mucosal Tissue Explants
Patient Surface Middle Basal Connective Age/Sex Race Alcohol/Tobacco history
1 ✓✓✓ ✓ 27F Asian/Pacific Islander None
2 ✓✓✓ ✓ 26F White/Non-Hispanic None
3 ✓ –– – 69F White/Non-Hispanic None
4 ✓ –– – 51M White/Non-Hispanic Prior alcohol and tobacco use
5
a ✓✓✓ ✓ 50M White/Non-Hispanic Cigar (5/day, 30 years) and alcohol consumption
6 ✓✓✓ ✓ 58F White/Non-Hispanic Regular alcohol consumption
7 ✓✓✓ ✓ 27F Asian/Pacific Islander Alcohol consumption (2/wk)
8 ✓ –– – 19M White/Non-Hispanic None
9 ✓✓✓ ✓ 18F White/Non-Hispanic Prior tobacco and current alcohol consumption
10 ✓✓✓ ✓ 19F Black/Non-Hispanic Regular alcohol consumption
Total 10 7 7 7
aFour specimens
FluoSphere penetration exhibited full-thickness penetration of the oral mucosa epithelium in seven of ten patient explants examined. Contrary to the
findings of Axford et al., two of the three negative penetration samples were from patients without an alcohol and/or tobacco history, while all patients
with current alcohol and/or tobacco usage exhibited full-thickness penetration (28).
Local Nanoparticle Delivery to Oral Mucosa 1233compatibility and to be metabolized in vitro by alcohol
dehydrogenase enzymes (34,35). Furthermore, other feasible
compounds, e.g., poly-lactic-co-glycolic acid formulations,
are routinely used, well tolerated, and fully functional in the
oral cavity (36).
Our data demonstrate, for the first time, that cultured
human OSCC cells internalize solid lipid nanoparticles.
This ability of SLNs to provide high, sustained intracellular
levels of fluorescent probe affords an avenue for both
compound stabilization and a mechanism to obtain a
local pharmacologic advantage. Relative to free-idarubicin
delivery, our data show greater sustained intracellular
idarubicin levels following nanoparticle delivery over the
extended treatment period. We speculate these data reflect
MRP1-mediated free-idarubicin efflux in the OSCC cell
lines (37). This speculation was substantiated by the
expression of MRP1 in all OSCC cell lines. The lack of
BCRP expression in cultured OSCC cells, which contrasts
with the presence of BCRP within OSCC tumor nests, is
likely attributable to the loss of BCRP during long-term
in vitro growth.
A previous study evaluated mRNA levels of multi-drug-
resistance-related genes [P-gp (mdr1), MRP (unspecified
isoform)] in normal human oral tissues (38). In contrast to
our findings, which demonstrate that normal oral mucosa
contains both BCRP and MRP1 proteins but lacks P-gp,
their data show increased mRNA levels of P-gp relative to
MRP (38). Because the oral cavity is the point of entry for
both the alimentary and pulmonary systems, it is physio-
logically beneficial to retain detoxification transporters at
the epithelial surface-external milieu interface. Further-
more, the highest phase-III levels were observed in the
basilar layers of the surface epithelium, which would
provide cytoprotection to proliferating basal layer epithelial
cells. Relative to the positive control MCF-7 cells, greater
levels of phase-III transporters were detected in oral
mucosa. These findings likely reflect the constant exposure
of oral tissues to foreign compounds. Because the MCF-7
cells were not challenged with xenobiotics, upregulation of
phase-III transporters did not occur. The observed lower
levels of BCRP and MRP1 in MCF-7 cells relative to
normal oral mucosa are consistent with the necessity for
detoxification by the respective cell populations.
Furthermore, the presence of MRP1 in the OSCC cell
lines appears to have influenced FluoSphere uptake. Our
quantitative FluoSphere data show a progressive increase in
intracellular levels over time in 2 of the 3 cell lines (i.e.,
SCC9 and SCC15). Interestingly, the SCC4 cell line, which
contains the highest levels of MRP1, exhibits a decrease in
FluoSphere concentration from the 6 to 24 h time points
(Fig.7A and C). This is consistent with the studies conducted
by Zhang et al., which showed conjugation of negatively
charged nanoparticles to glutathione and subsequent nano-
particle efflux from the cell via MRP-transporters (39).
Although minimal work has been conducted on SLN and
MRP interactions, recent studies show SLN-mediated
inhibition of the P-gp efflux pump and depletion of
intracellular ATP (20,40). It has also been reported that
the MRP1 nanoparticle efflux mechanism can be evaded by
maintaining a high concentration of nanoparticles at the
treatment site (41). In addition, recent studies suggest
COX-2 inhibition down-regulates MRP1 and BCRP
mRNA in oral cancer cells (42). Notably, our labs recently
demonstrated a significant reduction of COX-2 protein
concentrations following oral topical application of the
anthocyanin-rich FBR gel (11). These collective data imply
prolonged local oral SLN delivery of anthocyanins, and
fenretinide could circumvent MRP1-mediated efflux (i.e., via
concentration gradient maintenance, SLN-mediated inhibi-
tion, and anthocyanin, inhibition of COX-2) and achieve
therapeutically relevant levels in the target tissues. These
data also recapitulate the clinical finding that multiple
maintenance doses throughout the day represent the optimal
dosing strategy for topical formulations (25).
Oral cancer chemopreventives, which optimally redirect
growth of premalignant oral epithelium, require the thera-
peutic agents to reach the proliferating basal cell epithelial
layer. Consequently, while nanoparticle uptake by monolayer
epithelial cells is interesting, translational studies should
demonstrate nanoparticle penetration of intact, stratified
squamous surface epithelium. To date, percutaneous nano-
particle delivery systems have largely been unable to directly
penetrate the stratum corneum, but ocular transmucosal
nanoparticle delivery systems have shown more success
(32,43–45). A recent evaluation of a vitamin A-loaded SLN
topical delivery system did, however, successfully exhibit
vitamin A penetration across human cadaver skin (46).
Despite this finding, their failure to demonstrate direct
association of vitamin A diffusion with SLN penetration
does not definitively establish the feasibility of a trans-
epidermal topical nanoparticle delivery system (46). Further-
more, although the oral mucosal explant tissues used in our
studies were derived from gingival epithelium, which is more
keratinized and thicker than the anticipated common sites of
oral topical delivery (e.g., floor of mouth, ventral tongue,
oral vestibule), the surface epithelium was not as thick and
keratinized as epidermis. Also, many of the percutaneous
penetration studies were conducted on metabolically inactive
porcine skin or cadaver skin following fixation and/or
storage at −20°C for up to 2–4 weeks, which negates the
potential for endocytosis (32,43,46). In contrast, the oral
mucosal explants used in our study were incubated with
nanoparticles within 1 h of excision from the patients. These
characteristics, i.e., presence of viable mucosal tissue com-
bined with the decreased keratinization and epithelial
thickness, are likely responsible for the improved efficacy
1234 Holpuch et al.and observance of FluoSphere penetration into the basal
third and superficial underlying connective tissue in seven of
the ten patient explants examined.
These results are particularly promising due to the size
of the FluoSpheres (200 nm), a dimension roughly twice the
size of the model SLNs, and the negative surface charge of
both the SLNs and FluoSpheres. As previously shown by
Illum et al., positively charged nanoparticles provide an
advantage in mucosal delivery due to their ability to adsorb
to the negatively charged mucosal cells (45,47). Therefore,
the capacity of normal stratified oral squamous epithelium
to allow the penetration and subsequent internalization of
negatively charged nanoparticles is particularly promising.
Furthermore, the retention of the FluoSpheres in the deep
layers of oral epithelium expressing MRP1 and BCRP
(Fig. 8C and D) demonstrates the potential to overcome
phase-III efflux transporters by maintaining a concentration
gradient at the target site. These data introduce the
prospect for sustained local oral delivery of poorly water
soluble and unstable compounds, e.g., fenretinide, in
nanoparticle formulations.
While the objective of this study was to evaluate the
feasibility of local oral mucosal delivery with nanoparticle
formulations, the observed penetration of nanoparticles
through the epithelium and basement membrane into the
underlying connective tissue suggests the possibility of
oral transmucosal nanoparticle delivery for systemic thera-
peutics. These nanoparticle findings are consistent with our
previous mucosal penetration studies, which showed in vivo
systemic uptake of calcitonin and testosterone via buccal
transmucosal delivery from mucoadhesive delivery agents
(22,48). Collectively, these studies by our laboratories
address the main limitations previously reviewed by
Madhav et al. of oral transmucosal drug delivery, i.e.,
stabilization of compounds using nanoparticles and their
subsequent loading and release from mucoadhesive bi-layer
thin film composites (TFC) intended for unidirectional
release to the epithelial cell membrane (27).
These data demonstrate nanoparticle internalization
by OSCC cells and support the premise that SLN-based
delivery results in higher final intracellular levels relative
to bolus administration. Furthermore, the oral mucosal
explant data confirm the feasibility of using nanoparticles
to deliver chemopreventives to an optimal oral cavity
chemoprevention target, i.e., the proliferating, basal layer
epithelial cells, but also open the possibility of oral
transmucosal nanoparticle delivery for systemic therapeutic
applications.
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